Key result
Amisulpride treatment at 800 mg/d was associated with asymptomatic sinus bradycardia and QT prolongation, which quickly normalized when the dose was reduced to 600 mg/d.
Case Report (n=1)
Amisulpride treatment may be associated with the rare, reversible complication of asymptomatic sinus bradycardia and QT prolongation.
May prompt ECG monitoring at high-dose amisulpride; leaves open prevalence and generalizability in larger cohorts.
Well-known adverse effects of amisulpride include nausea, insomnia or tiredness, gastrointestinal, extrapyramidal and endocrine symptoms. Cardiac disorders, however, appear to be an extremely rare complication of the drug. Only a few case reports on this complication have been published so far, which deal with QT prolongation, hypotension, hypertension and palpitations. Bradycardia has not yet been mentioned. Here, we will report on a case of asymptomatic bradycardia that developed subsequent to therapeutic doses of amisulpride in a 25-year-old male patient with chronic paranoid-hallucinatory schizophrenia. The patient had been rehospitalized for an acute exacerbation of the psychosis. When the patient failed to respond at the beginning of hospitalization, the treatment was changed from clozapine to amisulpride. After a complete switchover to amisulpride, the patient's ECG showed sinus bradycardia and QT prolongation. When the daily dose of amisulpride was reduced from 800 mg/d to 600 mg/d, the patient's ECG quickly normalized (including blood pressure and pulse rate) within a few days. The patient did not report any cardiovascular-related complaints. Since the cardiovascular-specific diagnostics did not yield any indicative results, bradycardia may be a rare complication of amisulpride treatment.
No takes yet. Share an insight, caveat, or question.
Gil et al. (2001) conducted a case report in Chronic paranoid-hallucinatory schizophrenia (n=1). Amisulpride was evaluated on Asymptomatic sinus bradycardia and QT prolongation. Amisulpride treatment at 800 mg/d was associated with asymptomatic sinus bradycardia and QT prolongation, which quickly normalized when the dose was reduced to 600 mg/d.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: